leisure time -WSS

leisure time

author：entertainment 2025-09-27 19:29:20 - browse：79494

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Bird flu outbreak in cows is latest avian flu curveball

explore

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Key Senate committee drafts bipartisan bill to stem drug shortages

As health system earnings go up, health insurance stocks go down

Brain technologies pose threats that are all too real, experts warn

Bird flu in milk supply is likely coming from asymptomatic cows

Chemotherapy before breast cancer surgery might fuel metastasis

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Why rehabilitation engineers need to center patients in their research

Sports medicine is finally prioritizing gender equality

Element Biosciences CEO lays out genome sequencing strategy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Tori Bowie and the unacceptable rates of Black maternal death

HHS's proposed rule does nothing to address the climate crisis

How to save PrEP access — and even expand it

Cue Health's Covid

leisure time

Element Biosciences CEO lays out genome sequencing strategy

More tobacco lobbyists active in statehouses

After traumatic brain injury, life support decisions can use more time

BIO to announce reorganization, senior leaders expected to depart

Empower primary care with adequate payments and technology

As health system earnings go up, health insurance stocks go down

entertainment

knowledge

explore

hotspot